Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending August 10, 2017. The document serves as a transaction notification regarding dealings in the company's ordinary shares by a Person Discharging Managerial Responsibilities (PDMR) and a person closely associated with them (PCA).
Key Financial Metrics
The filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a regulatory disclosure of a specific share transaction.
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Volume: 4,360 shares.
- Transaction Price: £0.00 (Nil consideration).
Material Changes
No material changes to the company's financial position or operations are reported. The filing details a private transfer of shares between spouses:
- Recipient: Mrs. V A Whyte (SVP & Company Secretary).
- Transferor: Mr. I W Whyte (PCA of Mrs. V A Whyte).
- Nature: Receipt of shares by the PDMR from her spouse for nil consideration.
Guidance, Outlook, and Risks
The filing text does not provide any management commentary, future guidance, outlook, risk factors, contingencies, or unusual items. The document is limited to the statutory notification of the share transfer.
Investor Verification Points
- Verify the total shareholding of Mrs. V A Whyte following this transfer to assess potential insider ownership concentration.
- Confirm that the nil consideration transfer complies with GSK's internal trading policies and relevant securities regulations.
- Note that this filing contains no operational or financial updates; refer to the most recent Form 20-F or interim results for financial metrics.